{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:33:20Z","timestamp":1792978400571,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12282-026-01924-6","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:21:04Z","timestamp":1791177664000},"page":"1241-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preoperative CA15-3 as a predictor of axillary lymph node metastasis and prognosis in women with breast cancer: a GRADE-assessed systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Mansour","family":"Bahardoust","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Hosseinali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golnaz","family":"Ranjbarpazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meisam","family":"Haghmoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoboo","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Nafissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"3","key":"1924_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"Cancer J Clin"},{"issue":"8","key":"1924_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrc1670","volume":"5","author":"B Weigelt","year":"2005","unstructured":"Weigelt B, Peterse JL, Van\u2019t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591\u2013602.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1924_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H","volume":"63","author":"CL Carter","year":"1989","unstructured":"Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181\u20137.","journal-title":"Cancer"},{"issue":"6","key":"1924_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"1924_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jons.2017.01.001","volume":"3","author":"AM Kabel","year":"2017","unstructured":"Kabel AM. Tumor markers of breast cancer: new prospectives. J Oncological Sci. 2017;3(1):5\u201311.","journal-title":"J Oncological Sci"},{"issue":"33","key":"1924_CR6","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287\u2013312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1924_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cancers11040494","volume":"11","author":"Q Liu","year":"2019","unstructured":"Liu Q, Hu P. Association analysis of deep genomic features extracted by denoising autoencoders in breast cancer. Cancers. 2019;11(4):494.","journal-title":"Cancers"},{"issue":"1","key":"1924_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BF00666074","volume":"33","author":"H Iwase","year":"1995","unstructured":"Iwase H, et al. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat. 1995;33(1):83\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1924_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/jjco\/hyq190","volume":"41","author":"T Fujita","year":"2011","unstructured":"Fujita T, et al. CSLEX (Sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients. Jpn J Clin Oncol. 2011;41(3):394\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"1924_CR10","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.7314\/APJCP.2012.13.10.5257","volume":"13","author":"M Begum","year":"2012","unstructured":"Begum M, et al. CA 15\u2009\u2013\u20093 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev. 2012;13(10):5257\u201361.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1924_CR11","doi-asserted-by":"publisher","first-page":"100312","DOI":"10.1016\/j.jlb.2025.100312","volume":"9","author":"ML Schiavone","year":"2025","unstructured":"Schiavone ML, et al. Liquid biopsy in breast cancer: redefining precision medicine. J Liquid Biopsy. 2025;9:100312.","journal-title":"J Liquid Biopsy"},{"issue":"1","key":"1924_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13000-025-01745-9","volume":"21","author":"DM Thabet","year":"2026","unstructured":"Thabet DM, Abu Bakr A. Immunohistochemical expression of CANT1 and B3GNT3 in invasive ductal carcinoma of the breast: diagnostic and prognostic significance in lymph node metastasis. Diagn Pathol. 2026;21(1):12.","journal-title":"Diagn Pathol"},{"issue":"1","key":"1924_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Therapy. 2024;9(1):132.","journal-title":"Signal Transduct Target Therapy"},{"key":"1924_CR14","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.12659\/MSM.896563","volume":"22","author":"Y Fu","year":"2016","unstructured":"Fu Y, Li H. Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Monit. 2016;22:3154\u201362.","journal-title":"Med Sci Monit"},{"issue":"1","key":"1924_CR15","first-page":"9863092","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, et al. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: a meta\u2010analysis including 12,993 patients. Dis Markers. 2018;2018(1):9863092.","journal-title":"Dis Markers"},{"issue":"6","key":"1924_CR16","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.2001.19.6.1865","volume":"19","author":"RC Bast Jr","year":"2001","unstructured":"Bast RC Jr, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865\u201378.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1924_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7150\/jca.13090","volume":"7","author":"SG Wu","year":"2016","unstructured":"Wu SG, et al. Use of CEA and CA15-3 to predict axillary lymph node metastasis in patients with breast cancer. J Cancer. 2016;7(1):37\u201341.","journal-title":"J Cancer"},{"issue":"4","key":"1924_CR18","first-page":"4679","volume":"16","author":"X Li","year":"2018","unstructured":"Li X, et al. Determination of the prognostic value of preoperative CA15-3 and CEA in predicting the prognosis of young patients with breast cancer. Oncol Lett. 2018;16(4):4679\u201388.","journal-title":"Oncol Lett"},{"issue":"3","key":"1924_CR19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3892\/mmr.2017.6138","volume":"15","author":"X Jiang","year":"2017","unstructured":"Jiang X, et al. Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis. Mol Med Rep. 2017;15(3):1123\u201334.","journal-title":"Mol Med Rep"},{"key":"1924_CR20","unstructured":"Page MJ et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021. p 372."},{"issue":"1","key":"1924_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.","journal-title":"Trials"},{"key":"1924_CR22","first-page":"1","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"J Peterson","year":"2011","unstructured":"Peterson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Volume 2. Ottawa: Ottawa Hospital Research Institute; 2011. pp. 1\u201312. 1."},{"issue":"7650","key":"1924_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"7414","key":"1924_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"3","key":"1924_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/biostatistics\/1.3.247","volume":"1","author":"J Copas","year":"2000","unstructured":"Copas J, Shi JQ. Meta-analysis, funnel plots and sensitivity analysis. Biostatistics. 2000;1(3):247\u201362.","journal-title":"Biostatistics"},{"issue":"5","key":"1924_CR26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/ije\/dyn065","volume":"37","author":"NA Patsopoulos","year":"2008","unstructured":"Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37(5):1148\u201357.","journal-title":"Int J Epidemiol"},{"issue":"7109","key":"1924_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"key":"1924_CR28","doi-asserted-by":"crossref","unstructured":"Sterne JA et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 2011. p 343.","DOI":"10.1136\/bmj.d4002"},{"issue":"1","key":"1924_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.24126\/jobrc.2014.8.1.308","volume":"8","author":"RS Al-Hussain","year":"2014","unstructured":"Al-Hussain RS, et al. Early detection of breast cancer by tumor marker CA15. 3, CA27. 29 and relationship with P53 and vitamin D. J Biotechnol Res Cent. 2014;8(1):59\u201365.","journal-title":"J Biotechnol Res Cent"},{"issue":"8","key":"1924_CR30","doi-asserted-by":"publisher","first-page":"e0161902","DOI":"10.1371\/journal.pone.0161902","volume":"11","author":"D Dai","year":"2016","unstructured":"Dai D, et al. Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS ONE. 2016;11(8):e0161902.","journal-title":"PLoS ONE"},{"key":"1924_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12885-016-2448-1","volume":"16","author":"A Darlix","year":"2016","unstructured":"Darlix A, et al. Serum HER2 extra-cellular domain, S100\u00df and CA 15\u2009\u2013\u20093 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016;16:428.","journal-title":"BMC Cancer"},{"key":"1924_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cca.2014.11.001","volume":"440","author":"D Di Gioia","year":"2015","unstructured":"Di Gioia D, et al. Serum HER2 in combination with CA 15\u2009\u2013\u20093 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015;440:16\u201322.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1924_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1373\/clinchem.2003.025288","volume":"50","author":"MJ Duffy","year":"2004","unstructured":"Duffy MJ, et al. High preoperative CA 15\u2009\u2013\u20093 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50(3):559\u201363.","journal-title":"Clin Chem"},{"issue":"4","key":"1924_CR34","doi-asserted-by":"publisher","first-page":"BMT50","DOI":"10.2217\/bmt-2020-0015","volume":"9","author":"G Gaughran","year":"2020","unstructured":"Gaughran G, et al. The utility of the tumor markers CA15. 3, CEA, CA-125 and CA19. 9 in metastatic breast cancer. Breast Cancer Manage. 2020;9(4):BMT50.","journal-title":"Breast Cancer Manage"},{"key":"1924_CR35","doi-asserted-by":"crossref","unstructured":"He Z-Y et al. Elevated serum carcinoembryonic antigen and CA15-3 levels and the risk of site-specific metastases in metastatic breast cancer. Translational Cancer Res, 2016. 5(5).","DOI":"10.21037\/tcr.2016.08.39"},{"issue":"1","key":"1924_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12957-018-1325-6","volume":"16","author":"M Imamura","year":"2018","unstructured":"Imamura M, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15\u20133 levels for early breast cancer subtypes. World J Surg Oncol. 2018;16(1):26.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"1924_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1020514925143","volume":"76","author":"EJ Kumpulainen","year":"2002","unstructured":"Kumpulainen EJ, Keskikuru RJ, Johansson RT. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res Treat. 2002;76(2):95\u2013102.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1924_CR38","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/annonc\/mds604","volume":"24","author":"JS Lee","year":"2013","unstructured":"Lee JS, et al. Elevated levels of preoperative CA 15\u2009\u2013\u20093 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol. 2013;24(5):1225\u201331.","journal-title":"Ann Oncol"},{"issue":"1","key":"1924_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jss.2014.02.048","volume":"189","author":"H Li","year":"2014","unstructured":"Li H, et al. Preoperative CA 15\u2009\u2013\u20093 levels predict the prognosis of nonmetastatic luminal A breast cancer. J Surg Res. 2014;189(1):48\u201356.","journal-title":"J Surg Res"},{"issue":"4","key":"1924_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12282-020-01058-3","volume":"27","author":"J Li","year":"2020","unstructured":"Li J, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020;27(4):621\u201330.","journal-title":"Breast Cancer"},{"issue":"12","key":"1924_CR41","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.18240\/ijo.2024.12.15","volume":"17","author":"QC Liu","year":"2024","unstructured":"Liu QC, et al. Predictive value of CA-153, CA-125 and Apo A for ocular metastasis in menopausal female patients with breast cancer. Int J Ophthalmol. 2024;17(12):2265\u201375.","journal-title":"Int J Ophthalmol"},{"issue":"5B","key":"1924_CR42","first-page":"3965","volume":"26","author":"A Martin","year":"2006","unstructured":"Martin A, et al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res. 2006;26(5B):3965\u201371.","journal-title":"Anticancer Res"},{"issue":"3","key":"1924_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13277-010-0025-9","volume":"31","author":"R Molina","year":"2010","unstructured":"Molina R, et al. Evaluation of tumor markers (HER-2\/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol. 2010;31(3):171\u201380.","journal-title":"Tumour Biol"},{"issue":"7","key":"1924_CR44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1373\/clinchem.2009.135566","volume":"56","author":"R Molina","year":"2010","unstructured":"Molina R, et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem. 2010;56(7):1148\u201357.","journal-title":"Clin Chem"},{"issue":"3","key":"1924_CR45","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10549-019-05357-y","volume":"177","author":"SE Nam","year":"2019","unstructured":"Nam SE, et al. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat. 2019;177(3):669\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1924_CR46","first-page":"293","volume":"33","author":"B Nisman","year":"2013","unstructured":"Nisman B, et al. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer. Anticancer Res. 2013;33(1):293\u20139.","journal-title":"Anticancer Res"},{"issue":"4","key":"1924_CR47","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/annonc\/mdm538","volume":"19","author":"B-W Park","year":"2008","unstructured":"Park B-W, et al. Preoperative CA 15\u2009\u2013\u20093 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol. 2008;19(4):675\u201381.","journal-title":"Ann Oncol"},{"issue":"2","key":"1924_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4048\/jbc.2023.26.e17","volume":"26","author":"JM Ryu","year":"2023","unstructured":"Ryu JM, et al. Prognostic Impact of Elevation of Cancer Antigen 15\u20133 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level. J Breast Cancer. 2023;26(2):126\u201335.","journal-title":"J Breast Cancer"},{"issue":"1","key":"1924_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10549-011-1863-x","volume":"132","author":"MT Sandri","year":"2012","unstructured":"Sandri MT, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat. 2012;132(1):317\u201326.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1924_CR50","doi-asserted-by":"publisher","first-page":"e0133830","DOI":"10.1371\/journal.pone.0133830","volume":"10","author":"Y Shao","year":"2015","unstructured":"Shao Y, et al. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE. 2015;10(7):e0133830.","journal-title":"PLoS ONE"},{"issue":"12","key":"1924_CR51","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2521::AID-CNCR17>3.0.CO;2-A","volume":"83","author":"SG Shering","year":"1998","unstructured":"Shering SG, et al. Preoperative CA 15\u20133 concentrations predict outcome of patients with breast carcinoma. Cancer. 1998;83(12):2521\u20137.","journal-title":"Cancer"},{"issue":"5","key":"1924_CR52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3109\/1354750X.2010.482672","volume":"15","author":"S Turanli","year":"2010","unstructured":"Turanli S, Cetin A. Prognostic role of serum cancer antigen 15\u2009\u20133 in breast cancer patients with isolated bone metastases. Biomarkers. 2010;15(5):418\u201323.","journal-title":"Biomarkers"},{"issue":"1","key":"1924_CR53","first-page":"1","volume":"45","author":"A Vali\u0107","year":"2017","unstructured":"Vali\u0107 A, et al. Prognostic significance of CA 15\u20133 tumor marker in breast cancer patients. Libri oncologici: Croatian J Oncol. 2017;45(1):1\u20138.","journal-title":"Libri oncologici: Croatian J Oncol"},{"issue":"3","key":"1924_CR54","first-page":"445","volume":"9","author":"S Velaiutham","year":"2008","unstructured":"Velaiutham S, et al. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pac J Cancer Prev. 2008;9(3):445\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"1924_CR55","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.3390\/ijms15069546","volume":"15","author":"G Wang","year":"2014","unstructured":"Wang G, et al. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci. 2014;15(6):9546\u201365.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1924_CR56","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2013.11.003","volume":"23","author":"SG Wu","year":"2014","unstructured":"Wu SG, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88\u201393.","journal-title":"Breast"},{"issue":"10","key":"1924_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.14740\/jocmr5237","volume":"16","author":"Y Yilihamu","year":"2024","unstructured":"Yilihamu Y, et al. The Effects of preoperative serum carcinoembryonic antigen, cancer antigen 15\u2009\u2013\u20093 and cancer antigen 125 on the prognosis of breast cancer patients with different molecular subtypes. J Clin Med Res. 2024;16(10):491\u2013502.","journal-title":"J Clin Med Res"},{"issue":"1","key":"1924_CR58","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1038\/s41467-024-51995-2","volume":"15","author":"I Godet","year":"2024","unstructured":"Godet I, et al. Hypoxia induces ROS-resistant memory upon reoxygenation in vivo promoting metastasis in part via MUC1-C. Nat Commun. 2024;15(1):8416.","journal-title":"Nat Commun"},{"key":"1924_CR59","doi-asserted-by":"crossref","unstructured":"Chen W et al. MUC1: Structure, Function, and Clinic Application in Epithelial Cancers. Int J Mol Sci, 2021. 22(12).","DOI":"10.3390\/ijms22126567"},{"issue":"3","key":"1924_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3892\/or.2025.8942","volume":"54","author":"Y-F Li","year":"2025","unstructured":"Li Y-F, et al. Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer. Oncol Rep. 2025;54(3):109.","journal-title":"Oncol Rep"},{"issue":"160","key":"1924_CR61","doi-asserted-by":"publisher","first-page":"ra9","DOI":"10.1126\/scisignal.2001426","volume":"4","author":"R Ahmad","year":"2011","unstructured":"Ahmad R, et al. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011;4(160):ra9.","journal-title":"Sci Signal"},{"issue":"4","key":"1924_CR62","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3892\/or.2015.3783","volume":"33","author":"C Zhang","year":"2015","unstructured":"Zhang C, et al. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells. Oncol Rep. 2015;33(4):1872\u201382.","journal-title":"Oncol Rep"},{"key":"1924_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/IJWH.S162867","volume":"10","author":"LK Mudduwa","year":"2018","unstructured":"Mudduwa LK, et al. Elevated pre-surgical CA15-3: does it predict the short-term disease-free survival of breast cancer patients without distant metastasis? Int J Womens Health. 2018;10:329\u201335.","journal-title":"Int J Womens Health"},{"issue":"1","key":"1924_CR64","first-page":"5824491","volume":"2025","author":"S Saharti","year":"2025","unstructured":"Saharti S, Qari M. Elevated CA15-3 levels in myeloid disorders: clinicopathological correlation. Eur J Cancer Care. 2025;2025(1):5824491.","journal-title":"Eur J Cancer Care"},{"issue":"1","key":"1924_CR65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s44178-026-00257-w","volume":"5","author":"K Qian","year":"2026","unstructured":"Qian K, et al. MUC1 in cancer. Holist Integr Oncol. 2026;5(1):32.","journal-title":"Holist Integr Oncol"},{"issue":"2","key":"1924_CR66","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4161\/cam.23131","volume":"7","author":"TM Horm","year":"2013","unstructured":"Horm TM, Schroeder JA. MUC1 and metastatic cancer. Cell Adhes Migr. 2013;7(2):187\u201398.","journal-title":"Cell Adhes Migr"},{"issue":"1","key":"1924_CR67","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s12672-025-03030-z","volume":"16","author":"A Palollathil","year":"2025","unstructured":"Palollathil A, et al. The network map of mucin 1 mediated signaling in cancer progression and immune modulation. Discov Oncol. 2025;16(1):1404.","journal-title":"Discov Oncol"},{"issue":"6","key":"1924_CR68","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332\u201342.","journal-title":"Trends Mol Med"},{"issue":"5","key":"1924_CR69","doi-asserted-by":"publisher","first-page":"e36753","DOI":"10.1371\/journal.pone.0036753","volume":"7","author":"SK Lau","year":"2012","unstructured":"Lau SK, et al. EGFR-mediated carcinoma cell metastasis mediated by integrin \u03b1v\u03b25 depends on activation of c-Src and cleavage of MUC1. PLoS ONE. 2012;7(5):e36753.","journal-title":"PLoS ONE"},{"issue":"3","key":"1924_CR70","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1158\/1541-7786.MCR-22-0772","volume":"21","author":"N Yamashita","year":"2023","unstructured":"Yamashita N, et al. MUC1-C dictates PBRM1-mediated chronic induction of interferon signaling, DNA damage resistance, and immunosuppression in triple-negative breast cancer. Mol Cancer Res. 2023;21(3):274\u201389.","journal-title":"Mol Cancer Res"},{"issue":"9","key":"1924_CR71","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/carcin\/bgaa082","volume":"41","author":"DW Kufe","year":"2020","unstructured":"Kufe DW. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020;41(9):1173\u201383.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1924_CR72","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/bcr3084","volume":"14","author":"MA Aleskandarany","year":"2012","unstructured":"Aleskandarany MA, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 2012;14(1):R3.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1924_CR73","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/ijc.70487","volume":"159","author":"G Pantelaiou-Prokaki","year":"2026","unstructured":"Pantelaiou-Prokaki G, et al. MUC1 as a survival effector of radiotherapy-induced epithelial hybrid states in basal-like breast cancer. Int J Cancer. 2026;159(5):1296\u2013310.","journal-title":"Int J Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01924-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01924-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:03:07Z","timestamp":1792976587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01924-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01924-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study as it constitutes a systematic review and meta-analysis of previously published aggregate data. This research did not involve direct contact with human subjects, animals, or individual patient data.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}